Research use only peptides: why they are not for human use

A "research use only" label does not make a peptide legal to sell for people. FDA judges a product by its intended use, shown by claims, marketing and how it is sold ^[5]. In warning letters, FDA has found that peptides labeled "for research use only" and "not intended for human use" were in fact drugs for human use, and unapproved new drugs ^{[2, 3]}.

What the label claims

Sellers put phrases like "for research use only", "not for human or veterinary use" or "not for human consumption" on vials and websites ^{[2, 3, 4]}. The idea is that the product is a lab chemical, not a medicine. But the label alone does not decide how federal law treats it ^{[2, 5]}.

How FDA decides what a product is

Federal rules say intended use means the objective intent of the people responsible for the labeling. That intent can be shown by labeling claims, advertising, spoken or written statements, or the circumstances of how the product is sold ^[5].

In a December 10, 2024 warning letter, FDA wrote that despite labels saying "FOR RESEARCH USE ONLY" and "NOT INTENDED FOR HUMAN USE," evidence from the seller's website showed the products were intended to be drugs for human use ^[2]. The products named included retatrutide, cagrilintide, semaglutide and sermorelin ^[2]. FDA said they were drugs under section 201(g)(1) of the FD&C Act because they were intended to treat disease or to affect the structure or function of the body ^[2].

An August 24, 2026 letter reached the same finding for products sold as semaglutide, tirzepatide, retatrutide, elamipretide, tesamorelin and bremelanotide ^[3]. FDA also pointed out that the seller offered a liquid for preparing the peptides, which provided the means to make an injectable drug for human use ^[3].

A December 12, 2025 letter applied the same reasoning to products sold as SARMs, including one sold as MK-677 ibutamoren, despite "research use only" statements ^[4].

The legal problem: unapproved new drugs

Once a product is a drug, the next question is approval. FDA found these products were "new drugs" with no approved application in effect ^{[2, 3]}. Selling them across state lines violates sections 301(d) and 505(a) of the FD&C Act ^{[2, 3]}. FDA warned that failing to fix the violations may lead to legal action, including seizure and injunction ^{[2, 3]}.

Why these products are not for human use

FDA gives several reasons for concern ^{[1, 3]}:

FDA says products falsely labeled "for research purposes" or "not for human consumption" have been sold directly to consumers for human use with dosing instructions. It calls them products of unknown quality that may be harmful to health ^[1].
FDA warns that illegally marketed versions of semaglutide and tirzepatide may be counterfeit, may contain the wrong or harmful ingredients, and may contain too little, too much or no active ingredient ^[1].
Injectable products are delivered directly into the body, sometimes into the bloodstream. FDA says this bypasses some of the body's key defenses against toxins and microorganisms ^[3].

For some peptides, the safety data are thin. For BPC-157, FDA says it has no, or only limited, safety information for the proposed routes, so it lacks enough information to know whether the drug would cause harm in humans ^[8].

Research use only is not compounding

A research chemical is also not a compounded drug. A licensed compounder under section 503A must use bulk substances made by an FDA-registered establishment, each with a valid certificate of analysis ^{[6, 7]}. FDA states that retatrutide and cagrilintide cannot be used in compounding under federal law. They are not components of FDA-approved drugs and have not been found safe and effective for any condition ^[1]. FDA has warned telehealth companies, ingredient distributors and outsourcing facilities over retatrutide ^[1]. For how compounding is regulated, see 503A vs 503B pharmacies ^[6].

Checking a peptide's status

The FDA Peptide Status Tracker shows each peptide's FDA approval and compounding status, with links to FDA sources ^{[1, 8]}. FDA posts its warning letters publicly and encourages people to report problems with drugs ^{[1, 2]}.

Frequently asked questions

Is it legal to sell peptides labeled research use only?

The label does not settle it. FDA has found that peptides labeled for research use only were drugs for human use and unapproved new drugs, in violation of sections 301(d) and 505(a) of the FD&C Act ^{[2, 3]}.

What does 'not for human consumption' mean on a peptide?

It is a seller's disclaimer. FDA looks at the product's intended use, shown by claims, marketing and how it is sold, and has rejected such disclaimers in warning letters ^{[3, 4, 5]}.

Why does FDA say research peptides are risky?

FDA says these products have been sold to consumers with dosing instructions, are of unknown quality and may be harmful. Illegal versions may hold the wrong ingredient or the wrong amount ^[1].

Are research use only peptides the same as compounded peptides?

No. A 503A compounder must use bulk substances from an FDA-registered establishment with a valid certificate of analysis. FDA says retatrutide and cagrilintide cannot be used in compounding under federal law ^{[1, 6]}.

Has FDA sent warning letters about research peptides?

Yes. Examples include letters dated December 10, 2024 and August 24, 2026, which covered GLP-1 peptides and others labeled for research use ^{[2, 3]}.

Is retatrutide approved by FDA?

No. FDA states retatrutide is not a component of an FDA-approved drug and has not been found safe and effective for any condition ^[1].